Results 121 to 130 of about 4,947,726 (309)

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

open access: yesMolecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce   +11 more
wiley   +1 more source

Globalization and access to drugs : implications of the WTO/TRIPS Agreement

open access: yes, 1999
WHO/DAP/98.9 rev98 ...
WHO Action Programme on Essential Drugs   +1 more
core  

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

open access: yesMolecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Action Programme on Essential Drugs : progress report 1996, interim report of the biennium 1996-1997

open access: yes, 1997
ONLINEDAP/MAC(9)/97.542 ...
WHO Action Programme on Essential Drugs
core  

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

open access: yesMolecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla   +9 more
wiley   +1 more source

Action Programme on Essential Drugs : interim report of the biennium 1998-1999 : February 1999

open access: yes, 1999
WHO/HTP/EDM/MAC(11)/99.462 ...
WHO Action Programme on Essential Drugs
core  

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Assistência farmacêutica na atenção básica de saúde: a experiência de três estados brasileiros

open access: yesCadernos de Saúde Pública
No contexto das mudanças ocorridas no sistema de fornecimento de medicamentos em nível nacional no Brasil, com destaque para a desativação da Central de Medicamentos (CEME), e da crescente descentralização das ações de saúde no âmbito do Sistema Único de
Marly Aparecida Elias Cosendey   +5 more
doaj  

Abastecimiento de medicamentos en unidades de primer nivel de atención de la Secretaría de Salud de México Drug supplies at Ministry of Health primary health care units in Mexico

open access: yesSalud Pública de México, 2001
Objetivo. Conocer el nivel de disponibilidad de algunos medicamentos esenciales (ME) en las unidades de primer nivel de atención de la Secretaría de Salud de México (SSA), a partir de una investigación realizada en 1996-1997. Material y métodos.
Octavio Gómez-Dantés   +4 more
doaj  

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

open access: yesMolecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy